Maintenance Therapies in Late-Life Depression
Nortriptyline
Processus pathologiques+1
+ Conditions pathologiques, signes et symptômes
+ Attributs de la maladie
Étude thérapeutique
Résumé
Date de début de l'étude : 1 mars 1989
Date à laquelle le premier participant a commencé l'étude.To determine whether elderly (60-80 years old) depressed patients who cannot sustain a remission without medication must be maintained at full acute-treatment dose. To compare the efficacy of full-dose vs half-dose nortriptyline (NT) in preventing recurrences of major depression in the elderly. To determine whether those patients who experience a recurrence while in a maintenance placebo condition (Study I) require 100 percent of their acute-treatment dose of NT to prevent subsequent recurrences or can be successfully maintained on 50 percent of their acute-treatment dose (Study II). Investigators expect a pool of 60 patients from Study I to become eligible for Study II (the full-dose/half-dose maintenance trial). After treatment of the recurrence and following 16 weeks of stabilization therapy, patients are randomized to 1 of 2 maintenance therapy cells: full-dose NT or half-dose NT. Maintenance lasts 2 years or until recurrence of major depression. The following are assessed: differences in recurrence rates and time to recurrence under full-dose vs half-dose conditions; differences in symptomatic ratings of depression, suicidal ideation, social adjustment, and side effects; and differences in compliance rates as determined by variability in level-to-dose (L/D) ratios. Exploratory data analyses are used to generate a hypothetical profile of elderly patients who can remain well on half-dose maintenance nortriptyline. For information on related studies, please follow these links: http://clinicaltrials.gov/show/NCT00178100 http://clinicaltrials.gov/show/NCT00177671
Protocole
Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.Traitement
Éligibilité
Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.Tout sexe
Le sexe biologique des participants éligibles à s'inscrire.De 60 à 80 ans
Tranche d'âge des participants éligibles à participer.Conditions
Pathologie
Critères
Inclusion Criteria: - Patients must have: Recurrence of major depression while in a maintenance placebo condition in the currently funded maintenance therapy protocol (Study I).